Quantcast
Home > Quotes > OBLN

Obalon Therapeutics, Inc. Common Stock (OBLN) Quote & Summary Data

OBLN 
$2.58
*  
0.01
0.39%
Get OBLN Alerts
*Delayed - data as of Jun. 20, 2018  -  Find a broker to begin trading OBLN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.62 / $ 2.55
Share Volume
41,120
50 Day Avg. Daily Volume
N/A
Previous Close
$ 2.57
52 Week High / Low
$ 11.54 / $ 2.09
Market Cap
45,337,084
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
41,120
50 Day Avg. Daily Volume:
N/A

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.32

Trading Range

The current last sale of $2.58 is 23.44% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.62 $ 11.54
 Low: $ 2.55 $ 2.09

Company Description (as filed with the SEC)

ITEM 1. Business BUSINESS OVERVIEW We are a vertically integrated medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people by facilitating weight loss. Our initial product offering is the Obalon balloon system, the first and only U.S. Food and Drug Administration, or FDA, approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. We believe the Obalon balloon system offers patients and physicians benefits over prior weight loss devices including, but not limited to: a favorable safety profile, improved patient tolerability and comfort, progressive weight loss with durable results, simple and convenient placement, and attractive economics for patients and physicians. In September 2016, we received premarket approval, or PMA, from the FDA, and commenced U.S. commercialization in January 2017.  ... More ...  

Risk Grade

Where does OBLN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.55
Open Date:
Jun. 20, 2018
Close Price:
$ 2.58
Close Date:
Jun. 20, 2018

Consensus Recommendation

Analyst Info